Trial · NCT05702879
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
NCT05702879, Unknown, Insel Gruppe AG, University Hospital Bern
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success. Trials, record NCT05702879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05702879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
- NCT number
- NCT05702879
- Status
- Unknown
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Conditions
- Ulcerative Colitis
- Interventions
- Ozanimod, TNF Inhibitor, Steroids, Vedolizumab, Ustekinumab
- First posted
- 2023-01-27
- Last updated
- 2023-12-06
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Development of a predictive score regarding success of anti-inflammatory therapy after start of a new treatment in ulcerative colitis | 4 months | The predictive microbiota signature will be developed using machine learning, considering clinical data, microbiota descriptors, and metabolic changes from day 0 to week 4 (see analysis). Clinical response will be defined as a decrease in the simple clinical colitis activity index (SCCAI) score by ≥3 points 25or to a level of ≤2.5 points 26 at 8 weeks after the start of anti-inflammatory treatment. |
| Secondary | Predicting clinical remission | 8 weeks | Assessment of the microbiota/metabolic signature predicting clinical remission (SSCAI \<2.5) |
| Secondary | Predicting clinical remission | 12 weeks | Assessment of the microbiota/metabolic signature predicting clinical remission (SSCAI \<2.5) |
| Secondary | Predicting clinical remission | 6 months | Assessment of the microbiota/metabolic signature predicting clinical remission (SSCAI \<2.5) |
| Secondary | Predicting clinical remission | 12 months | Assessment of the microbiota/metabolic signature predicting clinical remission (SSCAI \<2.5) |
| Secondary | Predicting calprotectin reduction | 2 weeks | Assessment of the microbiota/metabolic signature predicting a reduction in fecal calprotectin levels |
| Secondary | Predicting calprotectin reduction | 8 weeks | Assessment of the microbiota/metabolic signature predicting a reduction in fecal calprotectin levels |
| Secondary | Predicting calprotectin reduction | 12 weeks | Assessment of the microbiota/metabolic signature predicting a reduction in fecal calprotectin levels |
| Secondary | Predicting calprotectin reduction | 6 months | Assessment of the microbiota/metabolic signature predicting a reduction in fecal calprotectin levels |
| Secondary | Predicting calprotectin reduction | 12 months | Assessment of the microbiota/metabolic signature predicting a reduction in fecal calprotectin levels |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05702879
GET https://conductscience.org/api/trials/v1/NCT05702879/registered